cambridge's bluebird bio licenses delivery tech to novartis, gsk. november 17, 2014.
the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid..
suven life sciences' pashamylaram facility successfully completes usfda inspection